99.4% Purity
In Stock
SKU RP-AOD-5MG
AOD-9604 (5 mg)
- AOD-9604: synthetic hGH fragment 177-191 peptide (≥98% purity)
- β3-adrenergic receptor modulator for lipolysis research
- Laboratory use only
$53.00
Growth-Hormone Secretagogues
Growth hormone secretagogues, releasing hormones, and related peptides for endocrine research.
11 products found
99.4% Purity
In Stock
SKU RP-IGF-1MG
IGF-1 LR3 (1 mg)
- 83-AA Recombinant IGF-1 Analog: Long R3 modifications confer ~3× potency vs. native IGF-1 and 20-30h half-life, ≥98% purity
- Reduced IGFBP Binding / Dual Signaling: Bypasses IGFBP sequestration; activates IGF-1R via PI3K/Akt/mTOR and MAPK/ERK cascades
- Cell Culture & Preclinical Research: Replaces insulin at 200-fold lower concentrations; validated in 22+ peer-reviewed publications
$64.00
99.4% Purity
In Stock
SKU RP-IPAM-5MG
Ipamorelin (5 mg)
- Ipamorelin pentapeptide - selective GHS-R1a agonist with unique hormonal selectivity profile
- ≥98% purity, research-grade, EC₅₀ = 1
- 3 nmol/L
$64.00
99.4% Purity
In Stock
SKU RP-CJC-5MG
CJC-1295 With DAC (5mg)
- GHRH Analog with DAC: 30-amino acid peptide with albumin-binding technology, ≥98% purity
- Extended Half-Life: 5.8-8.1 day biological half-life via maleimide-albumin conjugation
- GH/IGF-1 Axis Research: Sustained 2-10 fold GH and 1.5-3 fold IGF-1 elevation studies
$45.00
99.4% Purity
In Stock
SKU RP-SERM
Sermorelin
- Compound: 29-amino acid synthetic GHRH(1-29)-NH₂; biologically active N-terminal fragment of human growth hormone-releasing hormone
- Mechanism: Binds GHRH-R on pituitary somatotrophs; activates Gs-cAMP-PKA-CREB signaling cascade for physiological pulsatile GH release under somatostatin feedback regulation
- Validation: Authorized 1990 (diagnostic) and 1997 (pediatric GH deficiency); extensively characterized in peer-reviewed endocrinology, neuroendocrinology, and oncology research
$39.00
99.4% Purity
In Stock
SKU RP-TESA-2MG
Tesamorelin (2mg)
- Synthetic GHRH Analog: 44-amino acid polypeptide with N-terminal trans-3-hexenoic acid modification; enhanced DPP-IV resistance extends half-life to 26–38 min vs. minutes for native GHRH; 150+ PubMed publications
- Physiological GH Axis Modulation: Selective GHRH-R agonist preserving pulsatile GH secretion patterns and IGF-1 feedback regulation; studied in clinical trials for metabolic effects in HIV-associated lipodystrophy
- Regulatory Status: Tesamorelin (Egrifta) authorized 2010 for HIV-associated lipodystrophy; Egrifta WR (F8 formulation) authorized March 2025 with reconstitution updates; ongoing research in neurocognitive and hepatic biology
$40.00
99.4% Purity
In Stock
SKU RP-HCG
HCG (5000)
- Glycoprotein Hormone (hCG): 237-amino acid heterodimer (α-subunit 92 aa + β-subunit 145 aa), ≥95% purity by SDS-PAGE, 5,000 IU per vial
- LHCGR Biased Agonism: cAMP/PKA steroidogenic signaling, EC₅₀ 107 pM — 5-fold more potent than LH for cAMP production
- Reproductive Endocrinology Research: GPCR signaling, steroidogenesis, and endometrial biology investigation
$54.00
99.4% Purity
In Stock
SKU RP-KISS-10MG
KISSPEPTIN (10mg)
- Master Reproductive Regulator: C-terminal decapeptide (YNWNSFGLRF-NH2), ≥95% purity
- KISS1R/GPR54 Agonist: 8-fold higher receptor affinity than kisspeptin-54 (Ki = 0.042 nM)
- GnRH Pulse Generator: Most potent GnRH neuron stimulator, 4-minute human plasma half-life
$55.00
99.4% Purity
In Stock
SKU RP-PEG-2MG
PEG-MGF (2mg)
- PEG-MGF (PEGylated Mechano Growth Factor) is a synthetic, stabilized form of the 24-amino acid MGF E-domain peptide derived from the IGF-1Ec splice variant
- Research shows it activates satellite cells, promotes myoblast proliferation via MAPK-ERK1/2 signaling, and demonstrates neuroprotective effects through PKCε/Nrf2/HO-1 pathways
$44.00
99.4% Purity
In Stock
SKU RC-MK2866-CAPSULES-25MG
MK2866 Capsules (25mg) 100 Count
- Lorem ipsum dolor sit amet, consectetur adipiscing elit
- Vestibulum sagittis orci ac odio dictum tincidunt
$124.00
99.4% Purity
In Stock
SKU RC-RAD140-CAPSULES-15MG
Rad140 Capsules (15mg) 60 Count
- Nonsteroidal SARM: Benzonitrile-oxadiazole scaffold with AR binding Ki 7 nM (comparable to DHT 10 nM), first described 2011, tissue-selective levator ani vs. prostate activity, oral bioavailability 27-75%
- Clinical Development: Phase 1 ER+/HER2- breast cancer (MTD 100 mg/day, t½ 44.7 hours), active Phase 1/2 trial (NCT05573126, Ellipses Pharma EP0062), discontinued for sarcopenia indications
- Safety Warnings: Dose-limiting hepatotoxicity (AST 59.1%, ALT 45.5%), cholestatic liver injury case reports, cardiotoxicity (myocarditis/myopericarditis), HPG axis suppression, WADA prohibited S1.2, not approved for medical use
$124.00